HomeCompareABIO vs YUM

ABIO vs YUM: Dividend Comparison 2026

ABIO yields 11.04% · YUM yields 1.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YUM wins by $66.5K in total portfolio value· pulled ahead in Year 7
10 years
ABIO
ABIO
● Live price
11.04%
Share price
$28.80
Annual div
$3.18
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.5K
Annual income
$2,204.34
Full ABIO calculator →
YUM
YUM
● Live price
1.86%
Share price
$154.59
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.9K
Annual income
$40,443.52
Full YUM calculator →

Portfolio growth — ABIO vs YUM

📍 YUM pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABIOYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABIO + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABIO pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABIO
Annual income on $10K today (after 15% tax)
$938.54/yr
After 10yr DRIP, annual income (after tax)
$1,873.69/yr
YUM
Annual income on $10K today (after 15% tax)
$158.35/yr
After 10yr DRIP, annual income (after tax)
$34,376.99/yr
At 15% tax rate, YUM beats the other by $32,503.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABIO + YUM for your $10,000?

ABIO: 50%YUM: 50%
100% YUM50/50100% ABIO
Portfolio after 10yr
$74.7K
Annual income
$21,323.93/yr
Blended yield
28.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

ABIO
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
0.7
Piotroski
2/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+12.0% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABIO buys
0
YUM buys
0
No recent congressional trades found for ABIO or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABIOYUM
Forward yield11.04%1.86%
Annual dividend / share$3.18$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$41.5K$107.9K
Annual income after 10y$2,204.34$40,443.52
Total dividends collected$16.5K$81.2K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold

Year-by-year: ABIO vs YUM ($10,000, DRIP)

YearABIO PortfolioABIO Income/yrYUM PortfolioYUM Income/yrGap
1$11,804$1,104.17$10,982$282.06+$822.00ABIO
2$13,849$1,218.11$12,189$438.29+$1.7KABIO
3$16,154$1,335.59$13,731$688.32+$2.4KABIO
4$18,740$1,455.97$15,789$1,097.12+$3.0KABIO
5$21,631$1,578.61$18,679$1,785.08+$3.0KABIO
6$24,848$1,702.89$22,975$2,988.18+$1.9KABIO
7← crossover$28,415$1,828.18$29,784$5,200.49$1.4KYUM
8$32,358$1,953.89$41,408$9,539.16$9.1KYUM
9$36,703$2,079.45$63,071$18,765.27$26.4KYUM
10$41,476$2,204.34$107,930$40,443.52$66.5KYUM

ABIO vs YUM: Complete Analysis 2026

ABIOStock

ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorado Prevention Center, the University of Colorado's Academic Research Organization to develop and commercialize Gencaro. The company was incorporated in 2004 and is headquartered in Westminster, Colorado.

Full ABIO Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this ABIO vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABIO vs SCHDABIO vs JEPIABIO vs OABIO vs KOABIO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.